Effect of chemical modifications on allergenic potency of peanut proteins

Ramon Bencharitiwong
*Icahn School of Medicine at Mount Sinai*

Hanneke P. M. van der Kleij
*HAL Allergy BV*

Stef J. Koppelman
*University of Nebraska-Lincoln, stefkoppelman@zonnet.nl*

Anna Nowak-Wegrzyn
*Icahn School of Medicine at Mount Sinai, anna.nowak-wegrzyn@mssm.edu*

Follow this and additional works at: [http://digitalcommons.unl.edu/foodsciefacpub](http://digitalcommons.unl.edu/foodsciefacpub)

Part of the [Food Science Commons](http://digitalcommons.unl.edu/foodsciefacpub)

Bencharitiwong, Ramon; van der Kleij, Hanneke P. M.; Koppelman, Stef J.; and Nowak-Wegrzyn, Anna, "Effect of chemical modifications on allergenic potency of peanut proteins" (2015). *Faculty Publications in Food Science and Technology*. 221.

[http://digitalcommons.unl.edu/foodsciefacpub/221](http://digitalcommons.unl.edu/foodsciefacpub/221)

This Article is brought to you for free and open access by the Food Science and Technology Department at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Faculty Publications in Food Science and Technology by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.
Effect of chemical modifications on allergenic potency of peanut proteins

Ramon Bencharitiwong, Ph.D.,1 Hanneke P.M. van der Kleij, Ph.D.,2 Stef J. Koppelman, Ph.D.,2 and Anna Nowak-Wegrzyn, M.D.1

ABSTRACT

Background: Modification of native peanut extracts could reduce adverse effects of peanut immunotherapy.

Objective: We sought to compare native and chemically modified crude peanut extract (CPE) and major peanut allergens Ara h 2 and Ara h 6 in a mediator-release assay based on the rat basophilic leukemia (RBL) cell line transfected with human Fce receptor.

Methods: Native Ara h 2/6 was reduced and alkylated (RA), with or without additional glutaraldehyde treatment (RAGA). CPE was reduced and alkylated. Sera of subjects with peanut allergy (16 males; median age 7 years) were used for overnight RBL-passive sensitization. Cells were stimulated with 0.1 pg/mL to 10 μg/mL of peanut. β-N-acetylhexosaminidase release (NHR) was used as a marker of RBL degranulation, expressed as a percentage of total degranulation caused by Triton X.

Results: Median peanut-specific immunoglobulin E was 233 kUA/L. Nineteen subjects were responders, NHR 10% in the mediator release assay. Responders had reduced NHR by RA and RAGA compared with the native Ara h 2/6. Modification resulted in a later onset of activation by 10- to 100-fold in concentration and a lowering of the maximum release. Modified RA-Ara h 2/6 and RAGA-Ara h 2/6 caused significantly lower maximum mediator release than native Ara h 2/6, at protein concentrations 0.1, 1, and 10 ng/mL (p < 0.001, < 0.001, and < 0.001, respectively, for RA; and < 0.001, 0.026, and 0.041, respectively, for RAGA). RA-CPE caused significantly lower maximum NHR than native CPE, at protein concentration 1 ng/mL (p < 0.001) and 10 ng/mL (p < 0.002). Responders had high rAra h 2 immunoglobulin E (mean, 61.1 kUA/L; p < 0.001) and higher NHR in mediator release assay to native Ara h 2/6 than CPE, which indicates that Ara h 2/6 were the most relevant peanut allergens in these responders.

Conclusions: Chemical modification of purified native Ara h 2 and Ara h 6 reduced mediator release in an in vitro assay ~100-fold, which indicates decreased allergenicity for further development of the alternative candidate for safe peanut immunotherapy.


Peanut allergy affects >1% of young children in the developed countries.1 Peanut is the major cause of severe and fatal food-induced anaphylaxis.2,3 Currently, there is no cure for peanut allergy.4 Prior studies demonstrated efficacy of subcutaneous peanut immunotherapy with crude peanut extract (CPE), however, with an unacceptable rate of serious adverse reactions.5 Therefore, novel approaches for peanut immunotherapy are desirable.6–9 Chemical modification could represent an effective strategy for adverse effect reduction in peanut immunotherapy.

In the United States, immunoglobulin (Ig) E antibodies to Ara h 1 and to Ara h 2 and its homolog, Ara h 6, were most often detected in subjects who were 90–100% peanut reactive, and were associated with increased risk for anaphylaxis, which indicates high allergenic potential in vivo.10–13 A novel approach to creating a hypoallergenic preparation of Ara h 2 and Ara h 6 involves chemical modification that results in low IgE binding and preserved immunogenicity.14 These chemical modifications reduced the IgE-binding ~100-fold in solid-phase immunoassays without reducing T-cell immunogenicity.15

An important question is whether the reduction of IgE-binding observed in solid-phase IgE-binding assays, such as the UniCAP system (Thermo Fisher Scientific, Portage, MI) and enzyme-linked immunosorbent assay, is functionally relevant. We sought to investigate the allergenicity of native and chemically modified CPE and the purified mix of Ara h 2 and Ara h 6 (Ara h 2/6) by using the in vitro mediator-release assay and passively sensitized with IgE antibodies from individuals with peanut allergy. The rat baso-
Table 1. Characteristics of 26 subjects with peanut reaction

<table>
<thead>
<tr>
<th>Responder No.*</th>
<th>Age (y)</th>
<th>Sex</th>
<th>Peanut-sIgE (kU/mL)</th>
<th>rAra h 2-sIgE (kU/mL)</th>
<th>Total IgE (kU/mL)</th>
<th>Peanut/Total IgE</th>
<th>rAra h 2/Total IgE</th>
<th>History of Reactions to Peanut</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>m</td>
<td>71.4</td>
<td>136</td>
<td>251</td>
<td>0.28</td>
<td>0.54</td>
<td>Urticaria, wheezing, emesis</td>
</tr>
<tr>
<td>2</td>
<td>2.5</td>
<td>m</td>
<td>40.3</td>
<td>47.4</td>
<td>97</td>
<td>0.42</td>
<td>0.49</td>
<td>Cough, wheezing, pruritus</td>
</tr>
<tr>
<td>3</td>
<td>3.5</td>
<td>f</td>
<td>49.4</td>
<td>62.1</td>
<td>183</td>
<td>0.27</td>
<td>0.34</td>
<td>Facial urticaria and angioedema, erythema</td>
</tr>
<tr>
<td>4</td>
<td>3.5</td>
<td>f</td>
<td>1110</td>
<td>65.4</td>
<td>275</td>
<td>4.0</td>
<td>0.24</td>
<td>Not exposed, always avoided based on high test results</td>
</tr>
<tr>
<td>5</td>
<td>4.5</td>
<td>m</td>
<td>1110</td>
<td>422</td>
<td>2244</td>
<td>0.49</td>
<td>0.19</td>
<td>Not exposed, always avoided based on high test results</td>
</tr>
<tr>
<td>6</td>
<td>5.5</td>
<td>f</td>
<td>307</td>
<td>93.6</td>
<td>553</td>
<td>0.56</td>
<td>0.17</td>
<td>Angioedema, urticaria, dyspnea, cough, rhinorrhea, emesis</td>
</tr>
<tr>
<td>7</td>
<td>5.5</td>
<td>m</td>
<td>252</td>
<td>186</td>
<td>599</td>
<td>0.42</td>
<td>0.31</td>
<td>Emesis, pruritus</td>
</tr>
<tr>
<td>8</td>
<td>5.5</td>
<td>m</td>
<td>342</td>
<td>159</td>
<td>1176</td>
<td>0.29</td>
<td>0.14</td>
<td>Not exposed, always avoided based on high test results</td>
</tr>
<tr>
<td>9</td>
<td>6</td>
<td>f</td>
<td>59.3</td>
<td>54.5</td>
<td>272</td>
<td>0.22</td>
<td>0.20</td>
<td>Urticaria, angioedema, flushing, pharyngeal pruritus</td>
</tr>
<tr>
<td>10</td>
<td>6</td>
<td>m</td>
<td>74.1</td>
<td>84.8</td>
<td>274</td>
<td>0.27</td>
<td>0.31</td>
<td>Rhinorrhea</td>
</tr>
<tr>
<td>11</td>
<td>7</td>
<td>m</td>
<td>79</td>
<td>37.9</td>
<td>184</td>
<td>0.43</td>
<td>0.21</td>
<td>Urticaria, emesis, wheezing, abdominal pain, throat tightness, dyspnea</td>
</tr>
<tr>
<td>12</td>
<td>7</td>
<td>f</td>
<td>233</td>
<td>129</td>
<td>596</td>
<td>0.39</td>
<td>0.22</td>
<td>Pruritus</td>
</tr>
<tr>
<td>13</td>
<td>7.5</td>
<td>f</td>
<td>214</td>
<td>132</td>
<td>413</td>
<td>0.52</td>
<td>0.32</td>
<td>Angioedema, urticaria</td>
</tr>
<tr>
<td>14</td>
<td>8.2</td>
<td>m</td>
<td>377</td>
<td>243</td>
<td>813</td>
<td>0.46</td>
<td>0.30</td>
<td>Angioedema, dyspnea, emesis</td>
</tr>
<tr>
<td>15</td>
<td>10</td>
<td>m</td>
<td>1870</td>
<td>531</td>
<td>4925</td>
<td>0.38</td>
<td>0.11</td>
<td>Angioedema, urticaria, wheezing, emesis</td>
</tr>
<tr>
<td>16</td>
<td>10</td>
<td>m</td>
<td>339</td>
<td>158</td>
<td>625</td>
<td>0.54</td>
<td>0.25</td>
<td>Not exposed, always avoided based on high test results</td>
</tr>
<tr>
<td>17</td>
<td>10</td>
<td>m</td>
<td>64.9</td>
<td>60</td>
<td>389</td>
<td>0.17</td>
<td>0.15</td>
<td>Pruritus</td>
</tr>
<tr>
<td>18</td>
<td>11</td>
<td>m</td>
<td>60.1</td>
<td>35</td>
<td>515</td>
<td>0.12</td>
<td>0.07</td>
<td>Angioedema, dyspnea, urticaria, emesis</td>
</tr>
<tr>
<td>19</td>
<td>11</td>
<td>f</td>
<td>258</td>
<td>149</td>
<td>386</td>
<td>0.67</td>
<td>0.39</td>
<td>Angioedema, urticaria, erythema, dyspnea, cough, rhinorrhea, throat tightness</td>
</tr>
</tbody>
</table>

Median (IQR) 6 (4.8–9.6) 233 (66.5–341.3) 129 (60.5–158.8) 413 (272.5–618.5) 0.42 (0.27–0.51) 0.24 (0.17–0.32)

Nonresponder No.

| 20 | 3.5 | m   | 137 | 39.8 | 3815 | 0.0 | 0.01 |
| 21 | 5.5 | m   | 19.5 | 15.2 | 155 | 0.1 | 0.10 |
| 22 | 7   | f   | 29 | 16.8 | 100 | 0.3 | 0.17 |
| 23 | 13  | m   | 20.8 | 21.6 | 608 | 0.0 | 0.04 |
| 24 | 13.5 | m   | 20.2 | 16 | 88 | 0.2 | 0.18 |
| 25 | 20 | f   | 54.7 | 65 | 174 | 0.3 | 0.37 |
| 26 | 35 | f   | 36.2 | 28.6 | 298 | 0.1 | 0.10 |

Median (IQR) 13 (5.9–18.4) 29 (20.4–50.0) 21.6 (16.2–37) 174 (113.8–530.5) 0.13 (0.057–0.28) 0.10 (0.05–0.18)

Responders vs nonresponders, p value 0.087# 0.002§ < 0.001§ 0.165# 0.026§ 0.034§

Total IgE and specific IgE (sIgE) were measured (range, < 2 [undetectable] to > 5000 and < 0.35 kU/mL [undetectable], respectively) by using the UniCAP system; we obtained specific IgE from the sera > 100 kU/mL by diluting 100 times in the sample diluent.

*Responders were defined as those whose sera produced maximum NHR ≥ 10% to CPE or native Ara h 2/6 at 1–10 ng/mL.

#p = not statistically significant, §p < 0.05 was considered statistically significant (SigmaStat 3.5, Mann-Whitney rank sum t-test).

IQR = interquartile range.
philic leukemia (RBL) cell line transfected with human FcεRI receptor were used because of their documented high affinity of human IgE binding and the ability to detect allergens at very low concentrations, which might not be detected in less-sensitive biochemical and immunochemical assays.16–20 Furthermore, the mediator-release assay can be performed with sera selected for optimal performance in a wide range of protein concentrations and experimental batch testing, and can be stored frozen for prolonged periods of time, which results in more cost-effectiveness and less variability than in the basophil activation test based on the donor basophils.

Findings

Subjects

Sera were obtained from 26 subjects with a convincing history of peanut allergy (16 males; median age 7 years, 25–75% interquartile range, 5.5–10) (Table 1). Subjects were recruited from the pediatric allergy practice at the Jaffe Food Allergy Institute. The study was
approved by the Icahn School of Medicine at Mount Sinai Institutional Review Board, and informed consent was obtained.

MATERIALS AND METHODS

CPE was prepared from defatted peanut (Virginia variety) flour and was subsequently reduced and alkylated (RA-CPE).14 CPE was prepared from defatted peanut flour (Virginia-type peanuts) and was subsequently reduced and alkylated (RA-CPE) by reducing the disulfide bonds and alkylating the resulting free cysteines. Ara h 2/6 was purified as published,7 and two forms of chemically modified Ara h 2/6 were prepared (RA-Ara h 2/6, as described for RA-CPE), and reduction and alklylation in combination with additional cross-linking by glutaraldehyde (RAGA-Ara h 2/6).14

A mediator-release assay was performed as previously described.19 Sera from the subjects with peanut allergy were used for an overnight passive sensitization of RBL cell lines. A serum pool made from equal parts of 10 individual sera of responders (sera: 1, 6, 7, 10, 11, 13, 15, 16, 17, and 19) (Table E1) with high peanut-, rAra h 1–, and rAra h 2–specific IgE antibody levels (mean, 352.9, 149.1, and 156.8 kUA/L, respectively) was used to optimize the peanut protein concentration range and serum dilution (1:20 and 1:40). Thereafter, RBL cells were stimulated with allergenic extracts at 10-fold dilutions from 0.1 pg/mL to 10 μg/mL and with serum dilution at 1:40 in triplicates. The extracts were used without a freeze-thaw cycle more than twice to avoid proteins refolding. Peanut allergen–induced NHR in the supernatant was used as a marker of RBL degranulation. Rabbit IgG antihuman polyclonal IgE (Bethyl Laboratories, Inc, Montgomery, TX) was used as a positive control.13 Results were expressed as the percentage of release from cells sensitized with individual serum minus spontaneous release (with buffer), which was then divided by total release with 1% Triton X-100 (Sigma-Aldrich, St. Louis, MO) as follows:

% NHR = ([release by allergen – spontaneous release]/release by Triton X) × 100%

The dilution that gave the half maximal release was calculated (ED₅₀). The reciprocal value of ED₅₀ (1/ED) was defined as the allergenic potency of the extract compared between native peanut extract and its modified form.

Nineteen responders were arbitrarily defined as those whose sera produced maximum NHR > 10% to CPE or native Ara h 2/6 at 1–10 ng/mL concentration. Peanut-, rAra h 2–specific IgE (sIgE), rAra h 2-sIgE/total IgE ratio, and peanut-sIgE/total IgE ratio measured by UniCAP system were significantly higher in responders than in nonresponders (Table 1).
RESULTS

The calculated allergenic potency and NHR dose-response curve of native extract and its modified form are shown in Fig. 1. Fig. 1, A and B represent native Ara h 2/6 and RA-Ara h 2/6; Fig. 1, C and D represent CPE and RA-CPE. NHR induced by chemically modified extracts was reduced compared with their native counterparts. (Tables 2 and 3) Chemical modification resulted in an onset of activation at a higher allergen concentration by 10-to 100-fold as well as in a lowering of the maximum NHR. Modified RA-Ara h 2/6 and RAGA-Ara h 2/6 caused significantly lower maximum mediator release than native Ara h 2/6 at protein concentrations 0.1, 1, and 10 ng/mL (p < 0.001, p < 0.001, p < 0.001, respectively, for RA; and at p < 0.001, 0.026, and 0.041, respectively, for RAGA) (Table 4). RA-CPE caused significantly lower maximum NHR than native CPE at protein concentrations 1 ng/mL (p < 0.001) and 10 ng/mL (p < 0.002) (Table 4). There was a significant positive correlation between rAra h 2-specific IgE and the maximum NHR induced by native and chemically modified peanut extracts (Table 5). Responders had high rAra h 2 IgE (mean, 61.1 kUA/L; p < 0.001) and had higher NHR in mediator release assay to native Ara h 2/6 than CPE (data not shown), which indicates that Ara h 2/6 was the most relevant peanut allergen in these responders. IgE antibody levels and mediator release were positively correlated and associated with responder status.19 We observed a similar association (Table 5).

DISCUSSION

We demonstrated that chemical modification of peanut resulted in ~100-fold reduction in mediator release in an in vitro assay, which indicates a significantly decreased allergenicity. This is in line with observations made for modified Ara h 2/6 when using a solid-phase IgE-binding assay and findings of a recent study performed in European adult subjects.15 We focused on conglutin storage Ara h 2 due to its high allergenic potency and resistance to digestive proteases pepsin and trypsin. In addition, Ara h 6 has a high homology of amino acid sequence to Ara h 2, especially in the middle part and at the C-terminal part of the protein from peanut. Koppelman et al.21 showed the cross-reactivity in IgE binding of purified Ara h 6 and Ara h 2 described as potent allergens in peanut. Vissers et al.22 reported that heat-induced conformation of native Ara h 2/6 purified after roasting retained its native forms and that extensively heat-induced denaturation did not affect the allergenic properties of Ara h 2/6 from roasted peanut. Thus, a chemical protein modification strategy could be used as an alternative approach to destroy allergenic peptide epitopes with maintained immunogenicity.

Table 4. Peanut allergen-induced NHR with 19 responder sera

<table>
<thead>
<tr>
<th>Responders, n = 19</th>
<th>Native Peanut Extract NHR, % (median 25–75% IQR)</th>
<th>Modified Peanut Extract NHR, % (median 25–75% IQR)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>At the maximum release</td>
<td>CPE 15.1 (7.2–26.8)</td>
<td>RA-CPE 12.2 (3.5–24.2)</td>
<td>0.189*</td>
</tr>
<tr>
<td></td>
<td>Ara h 2/6 18.5 (11.5–31.9)</td>
<td>RA-Ara h 2/6 5.2 (2.2–19.3)</td>
<td>0.001</td>
</tr>
<tr>
<td></td>
<td>RAGA-Ara h 2/6 9 (2.7–16.5)</td>
<td>0.001</td>
<td></td>
</tr>
<tr>
<td>At 0.1 ng/mL</td>
<td>CPE 1.7 (0.2–2.5)</td>
<td>RA-CPE 0.2 (0–1)</td>
<td>0.079*</td>
</tr>
<tr>
<td></td>
<td>Ara h 2/6 10.9 (8.2–17.5)</td>
<td>RA-Ara h 2/6 0.7 (0–3.9)</td>
<td>&lt; 0.001#</td>
</tr>
<tr>
<td></td>
<td>RAGA-Ara h 2/6 2.4 (0.6–4.4)</td>
<td>&lt; 0.001#</td>
<td></td>
</tr>
<tr>
<td>At 1 ng/mL</td>
<td>CPE 7.6 (2.6–12.9)</td>
<td>RA-CPE 0.8 (0.2–4.0)</td>
<td>&lt; 0.001#</td>
</tr>
<tr>
<td></td>
<td>Ara h 2/6 15.7 (9.3–31.9)</td>
<td>RA-Ara h 2/6 1.2 (0.4–9.0)</td>
<td>&lt; 0.001#</td>
</tr>
<tr>
<td></td>
<td>RAGA-Ara h 2/6 3.5 (0.7–9.0)</td>
<td>&lt; 0.001#</td>
<td></td>
</tr>
<tr>
<td>At 10 ng/mL</td>
<td>CPE 15.1 (7.2–25.9)</td>
<td>RA-CPE 3 (1–11.4)</td>
<td>0.002</td>
</tr>
<tr>
<td></td>
<td>Ara h 2/6 13.9 (3.5–28.6)</td>
<td>RA-Ara h 2/6 4.4 (1–17.8)</td>
<td>0.026</td>
</tr>
<tr>
<td></td>
<td>RAGA-Ara h 2/6 4.5 (2.1–13.1)</td>
<td>0.041</td>
<td></td>
</tr>
</tbody>
</table>

*p = not statistically significant, #p < 0.05 was considered statistically significant, (SigmaStat 3.5, Mann-Whitney rank sum t-test).

IQR = interquartile range.
We found that chemical modification of crude pea-
nut and purified native Ara h 2/6 reduced mediator
release in an in vitro mediator-release assay
100-fold, which indicates decreased allergenicity. Furthermore,
it can be performed with sera selected for optimal
performance in a wide range of protein concentrations
and experimental batch testing, and can be stored fro-
zened for prolonged periods of time, which results in
more cost-effectiveness and less variability of basophil
activation test from donors. We observed that some
nonresponder sera with high-specific IgE to peanut
and rAra h 2 induced a low mediator release, NHR
< 10%. This low release might be explained by lower IgE
antibody affinity, a lower number of recognized IgE-
binding epitopes, or dilution effect, in the presence of
high total IgE antibodies.

CONCLUSIONS
The confirmation of the decreased IgE binding of
chemically modified native peanut proteins is an im-
portant step for the further development of the alter-
native candidate for safe and successful peanut immu-
notherapy. However, the wide range of the individual
responses to chemically modified peanut proteins war-
rants caution and indicates that, before immunother-
apy with chemically modified peanut proteins, careful
patient characterization and selection must be consid-
ered.

ACKNOWLEDGMENTS
We thank Drs. Stefan Vieths and Lothar Vogel for kindly providing
the RBL cell line.

REFERENCES
1. Sicherer SH, and Sampson HA. Food allergy: Epidemiology,
pathogenesis, diagnosis, and treatment. J Allergy Clin Immunol
2. Bock SA, Munoz-Furlong A, and Sampson HA. Fatalities due to
anaphylactic reactions to foods. J Allergy Clin Immunol 107:
3. Dyer AA, Rivkina V, Perumal D, et al. Epidemiology of child-
to peanuts by immunotherapy with injections of aqueous peanut
6. Nowak-We˛grzyn A, and Albin S. Oral immunotherapy for food
allergy: Mechanisms and role in management. Clin Exp Allergy
7. Sun J, Hui X, Ying W, et al. Efficacy of allergen-specific immu-
notherapy for peanut allergy: A meta-analysis of randomized
8. Mansfield LE. Oral immunotherapy for peanut allergy in clini-
9. Greenhawt MJ. Oral and sublingual peanut immunotherapy is not
to whole peanut extract and peanut components in prediction of
Arachis hypogaea, Ara h 2 and Ara h 6, are the major elicitors of
anaphylaxis and can effectively desensitize peanut-allergic
tion of Ara h 2 to peanut-specific, immunoglobulin E-mediated,
potency of Ara h 1 and Ara h 2 in immunochemical and func-

Table 5. Peanut allergen-induced NHR; 10 responders with high specific IgE toward rAra h 2 and low
specific IgE against rAra h 1 < 35 kUA/L*

<table>
<thead>
<tr>
<th>CPE NHR, % (median 25–75% IQR)</th>
<th>Native Ara h2/6 Extract NHR, % (median 25–75% IQR)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>At the maximum release</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CPE</td>
<td>7.3 (5.6–12.4)</td>
<td>0.045</td>
</tr>
<tr>
<td>Ara h 2/6</td>
<td>16.4 (10.8–25.4)</td>
<td></td>
</tr>
<tr>
<td>At 0.01 ng/mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CPE</td>
<td>0.4 (0.05–1.6)</td>
<td>0.005</td>
</tr>
<tr>
<td>Ara h 2/6</td>
<td>8.4 (2.6–9.7)</td>
<td>&lt; 0.001#</td>
</tr>
<tr>
<td>At 0.1 ng/mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CPE</td>
<td>0.6 (0–1.7)</td>
<td></td>
</tr>
<tr>
<td>Ara h 2/6</td>
<td>10.8 (9–14.6)</td>
<td>0.005</td>
</tr>
<tr>
<td>At 1 ng/mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CPE</td>
<td>2.7 (2–7.3)</td>
<td></td>
</tr>
<tr>
<td>Ara h 2/6</td>
<td>13.2 (7.8–22.4)</td>
<td></td>
</tr>
</tbody>
</table>

*Specific IgE toward rAra h 1 (median, 17.5; median 25–75% interquartile range, 15.3–17.5) was significantly lower (p < 0.001) than specific IgE toward rAra h 2 (median, 61.1; median 25–75% interquartile range, 47.4–84.8).
#p < 0.05 was considered statistically significant; NS = not statistically significant (SigmaStat 3.5, Mann-Whitney rank sum t-test).
IQR = interquartile range.